Sio Gene Therapies Inc.
SIOXDelisted Apr 12, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636050
Sio Gene Therapies Inc. was delisted on Apr 12, 2023; its insiders filed their last Form 4 on Feb 10, 2022; 37 institutions reported holding it in 13F filings for Q4 2022, worth $8.09M in total; no superinvestor held it.
Q1 2022 vs. Q4 2021
How the institutions holding Sio Gene Therapies Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 48 | 40 | −8 |
| Shares | 21.3M | 18.1M | −3.23M (−15.1%) |
| Value | $27.6M | $12.1M | −$15.4M (−56.0%) |
New holders (3)
Institutions that held Sio Gene Therapies Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of Montreal | 10,000 | $7.00K | 0.00% |
| TCI Wealth Advisors, Inc. | 700 | $0 | 0.00% |
| Wolff Wiese Magana LLC | 400 | $0 | 0.00% |
Sold out (11)
Institutions that held Sio Gene Therapies Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Privium Fund Management B.V. | 1,806,542 | $2.37M |
| Ameriprise Financial Inc | 382,004 | $494.0K |
| Gsa Capital Partners LLP | 166,806 | $215.0K |
| Millennium Management LLC | 147,254 | $190.0K |
| Jane Street Group, LLC | 23,259 | $30.0K |
| Charles Schwab Investment Management Inc | 20,023 | $26.0K |
| UBS Group AG | 20,613 | $26.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 18,066 | $23.0K |
| Goldman Sachs Group Inc | 17,355 | $22.0K |
| FMR LLC | 1,000 | $1.00K |
| Edge Wealth Management LLC | 320 | $1.00K |